Moderna Shares Surge 100% on Skin Cancer Vaccine Success

Moderna's mRNA-1273 skin cancer vaccine, approved by the FDA, has driven the company's stock up 100%. The vaccine showed 90% efficacy, positioning it as a groundbreaking treatment.

■Moderna's market cap now exceeds $100 billion.

■CEO Stéphane Bancel stated, 'This vaccine could be a turning point in global healthcare.' - Competition from Pfizer and BioNTech is expected to keep pricing competitive.

■Baltic Dry Index (BDI) and global commodity prices rose due to increased demand for the vaccine.

Global supply chains may face disruptions as demand surges impact Suez Canal traffic and Panama Canal shipping costs. Moderna's success signals a future for mRNA-based therapies.

Moderna Shares Surge 100% on Skin Cancer Vaccine Success

Related News & Analysis

Prosus Injects $100 Million into Navi, Valuing It at $1.3 Billion Ahead of IPO

Will Netflix's 100% Rotten Tomatoes Score Create Value? Smart Investors Take Note!

Van Leeuwen vs. Rebel: The $23.8M Bankruptcy Behind the Chip Design War

Treasury's Liquidity Shield for Bond Markets Sparks Global Risk-On Rally

Beyond the Pitch: Football Stars Pivot to the Booming Chess Economy

US Treasury Doubles Down on Debt Buybacks to Quell Bond Market Inflation Panic

Latest Market News

TMO Sets First Opium Seed Purchase Price at 140 Lira/kg

[AVTUR] AVRASYA PETROL VE TURİSTİK TESİSLER YATIRIMLAR A.Ş. Sorumluluk Beyanı (Konsolide Olmayan) - Sorumluluk Beyanı

[AVTUR] AVRASYA PETROL VE TURİSTİK TESİSLER YATIRIMLAR A.Ş. Faaliyet Raporu (Konsolide Olmayan) - Faaliyet Raporu

[HATEK] HATEKS HATAY TEKSTİL İŞLETMELERİ A.Ş. Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu

[HATEK] HATEKS HATAY TEKSTİL İŞLETMELERİ A.Ş. Sorumluluk Beyanı (Konsolide) - 01.01.2026 - 30.06.2026 SORUMLULUK BEYANI

[AVTUR] AVRASYA PETROL VE TURİSTİK TESİSLER YATIRIMLAR A.Ş. Finansal Rapor - Finansal Rapor